Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL14441307 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL17359656 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL16072074 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13294189 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL14430016 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL18838926 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL20850040 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13014098 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234983-A1 | SQUALAMINE CRYSTALLINE POLYMORPHS | ENTERIN, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20210332079-A1 | SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME | Enterin, Inc (US) | 2021-10-28 | — | — | US | disclosed |
| US-20200262864-A1 | DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262864-A1 | DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME | DHCR7, HSD17B13, HSD11B2 | PTPN1 4755/4885NR1H4 47/4885SLC10A1 48/4885 |
| US-20230234983-A1 | SQUALAMINE CRYSTALLINE POLYMORPHS | HLA-DRB1, SLC10A2, HLA-A | PTPN1 812/4885NR1H4 305/4885SLC10A1 23/4885 |
| US-20210332079-A1 | SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME | SI, SUCLG1, TPMT | PTPN1 2755/4885NR1H4 2194/4885SLC10A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.